Idiopathic constipation

Too few stools and too little knowledge

Michel R. Briejer, Jan A J Schuurkes, Sushil K. Sarna

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The precise abnormalities of colonic motility patterns in idiopathic constipation, and the alterations at the cellular, neural, myogenic and biochemical levels that underlie these patterns, are not yet understood. One promising approach in the treatment of constipation seems to be to design drugs that can stimulate GMCs to produce mass movements and consequently defaecation. This could possibly be achieved with the selective 5-HT4 receptor agonists prucalopride and SDZ HTF-919, which are currently in advanced clinical trials. Other mechanisms that provide a means to induce GMCs, such as NK1 receptor agonism, deserve further exploration.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalTrends in Pharmacological Sciences
Volume20
Issue number1
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

prucalopride
Receptors, Serotonin, 5-HT4
Constipation
Serotonin 5-HT4 Receptor Agonists
Defecation
Drug Design
Pharmaceutical Preparations
Clinical Trials
tegaserod

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Idiopathic constipation : Too few stools and too little knowledge. / Briejer, Michel R.; Schuurkes, Jan A J; Sarna, Sushil K.

In: Trends in Pharmacological Sciences, Vol. 20, No. 1, 01.01.1999, p. 1-3.

Research output: Contribution to journalArticle

Briejer, Michel R. ; Schuurkes, Jan A J ; Sarna, Sushil K. / Idiopathic constipation : Too few stools and too little knowledge. In: Trends in Pharmacological Sciences. 1999 ; Vol. 20, No. 1. pp. 1-3.
@article{ef3b3f00e04e4987b44bed0eec93bf87,
title = "Idiopathic constipation: Too few stools and too little knowledge",
abstract = "The precise abnormalities of colonic motility patterns in idiopathic constipation, and the alterations at the cellular, neural, myogenic and biochemical levels that underlie these patterns, are not yet understood. One promising approach in the treatment of constipation seems to be to design drugs that can stimulate GMCs to produce mass movements and consequently defaecation. This could possibly be achieved with the selective 5-HT4 receptor agonists prucalopride and SDZ HTF-919, which are currently in advanced clinical trials. Other mechanisms that provide a means to induce GMCs, such as NK1 receptor agonism, deserve further exploration.",
author = "Briejer, {Michel R.} and Schuurkes, {Jan A J} and Sarna, {Sushil K.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1016/S0165-6147(98)01278-4",
language = "English (US)",
volume = "20",
pages = "1--3",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Idiopathic constipation

T2 - Too few stools and too little knowledge

AU - Briejer, Michel R.

AU - Schuurkes, Jan A J

AU - Sarna, Sushil K.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The precise abnormalities of colonic motility patterns in idiopathic constipation, and the alterations at the cellular, neural, myogenic and biochemical levels that underlie these patterns, are not yet understood. One promising approach in the treatment of constipation seems to be to design drugs that can stimulate GMCs to produce mass movements and consequently defaecation. This could possibly be achieved with the selective 5-HT4 receptor agonists prucalopride and SDZ HTF-919, which are currently in advanced clinical trials. Other mechanisms that provide a means to induce GMCs, such as NK1 receptor agonism, deserve further exploration.

AB - The precise abnormalities of colonic motility patterns in idiopathic constipation, and the alterations at the cellular, neural, myogenic and biochemical levels that underlie these patterns, are not yet understood. One promising approach in the treatment of constipation seems to be to design drugs that can stimulate GMCs to produce mass movements and consequently defaecation. This could possibly be achieved with the selective 5-HT4 receptor agonists prucalopride and SDZ HTF-919, which are currently in advanced clinical trials. Other mechanisms that provide a means to induce GMCs, such as NK1 receptor agonism, deserve further exploration.

UR - http://www.scopus.com/inward/record.url?scp=0032973841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032973841&partnerID=8YFLogxK

U2 - 10.1016/S0165-6147(98)01278-4

DO - 10.1016/S0165-6147(98)01278-4

M3 - Article

VL - 20

SP - 1

EP - 3

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 1

ER -